Friend or Foe: Prescription Drug Reimportation in the US - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Friend or Foe: Prescription Drug Reimportation in the US
Legislation has hampered cross-border drug importation and limited choice.


Pharmaceutical Technology
Volume 35, Issue 2, pp. 97-98

Potential remedies

But in the immediate future, reimportation remains a controversial issue. Making reimportation legal may not bring long-term benefits to the US market because of already mentioned concerns over safety. Reimportation also could reduce companies' revenue and thereby deplete funding for new-drug research and development.

American consumers will benefit most when drug prices are controlled at a global level. The authors propose the formation of an international body of pharmaceutical leaders to monitor the flow of pharmaceuticals across borders and to regulate prices internationally. (FDA and other regulatory agencies do not regulate prices.) An international consortium of pharmaceutical companies could work to find common ground with consumers on drug pricing internationally, which could reduce drug reimportation.

An active dialogue between company representatives and government representing American consumers also is necessary to keep drug reimportation off the table. Educating consumers about the risks of bringing drugs into the country illegaly is crucial, as is discussing alternatives to low-cost products.

Om V. Singh, PhD, is assistant professor in the Division of Biological and Health Sciences at the University of Pittsburgh in Bradford, PA,
. Thomas E. Colonna, PhD, is associate director of the Bioscience Regulatory Affairs Program in the Zanvyl Krieger School of Arts and Sciences at Johns Hopkins University in Washington, DC,
.

References

1. T.S. Rector and P.J. Venus, Health Aff. 23 (2004) 213–222.

2. D.G. Safran et al., Health Aff. Supp. web exclusive (2002), pp. W253–68.

3. Public Law 108-173, Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

4. HHS, Medicare Modernization Act Update–Overview, http://www.cms.gov/PrescriptionDrugCovGenIn/01_Overview.asp, accessed Jan. 5, 2011.

5. HHS, Report on Prescription Drug Importation (December 2004), http://archive.hhs.gov/importtaskforce/Report1220.pdf, accessed Dec. 1, 2010.

6. American Progress, "Prescription Drug Reimportation: The Law and Its Problems," http://www.americanprogress.org/kf/bgreimp.pdf, accessed Dec. 1, 2010.

7. US Congress, H.R. 1298: Pharmaceutical Market Access and Drug Safety Act of 2009, http://www.govtrack.us/congress/bill.xpd?bill=h111-1298, accessed Jan. 5, 2011.

8. HHS, FY2010 Budget in Brief, http://dhhs.gov/asfr/ob/docbudget/2010budgetinbrief.pdf, accessed Dec. 20 2010.

9. HHS, FY2010 Budget, http://www.gpoaccess.gov/usbudget/fy11/pdf/budget/health.pdf, accessed Dec. 20, 2010.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
21%
To all process for new products only
13%
To select process for new products only
26%
To select processes for both new and legacy products
21%
Do not use QbD
21%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
Overcoming the Challenges in Biopharmaceutical Stability Testing
PhRMA Dismayed by Special 301 Report
FindPharma Custom Search
Source: Pharmaceutical Technology,
Click here